SciBase Holding AB (publ)
STO:SCIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SciBase Holding AB (publ)
Net Income (Common)
SciBase Holding AB (publ)
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SciBase Holding AB (publ)
STO:SCIB
|
Net Income (Common)
-kr87.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-8%
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Net Income (Common)
-kr39m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Net Income (Common)
kr153.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Getinge AB
STO:GETI B
|
Net Income (Common)
kr2.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Net Income (Common)
kr334m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Net Income (Common)
kr55.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
46%
|
CAGR 10-Years
18%
|
|
SciBase Holding AB (publ)
Glance View
SciBase Holding AB is a global medical technology company, which engages in the development and sale of instruments for the detection of skin cancer and other skin diseases. The company is headquartered in Sundbyberg, Stockholm and currently employs 23 full-time employees. The company went IPO on 2015-06-02. The firm specializes in the manufacture of point of care device, called Nevisense, which is aimed to detect of malignant melanoma. Nevisense analyze suspicious lesions by using Electrical Impedance Spectroscopy (EIS) which is applied as an electrical signal to the skin. The diagnostic product is sold in Nordic countries, Belgium, Germany, Great Britain and Australia.
See Also
What is SciBase Holding AB (publ)'s Net Income (Common)?
Net Income (Common)
-87.1m
SEK
Based on the financial report for Dec 31, 2025, SciBase Holding AB (publ)'s Net Income (Common) amounts to -87.1m SEK.
What is SciBase Holding AB (publ)'s Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-8%
Over the last year, the Net Income (Common) growth was -42%. The average annual Net Income (Common) growth rates for SciBase Holding AB (publ) have been -26% over the past three years , -20% over the past five years , and -8% over the past ten years .
